Donisi Health Takes Home First Place in the Prestigious Innovations in Cardiovascular Intervention Competition
PR93561
TEL AVIV, Israel, December 10, 2021 /PRNewswire=KYODO JBN/--
MedTech Startup Focused on Home Monitoring for Patients with Congestive Heart
Failure and Other Chronic Diseases Wins the 2021 ICI Pitch Competition and
$200,000 Award
Donisi Health [https://donisihealth.com/](Donisi) prevailed in this year’s ICI
Innovation Competition – the premier international conference for innovations
in cardiovascular intervention. Competing against startups from all over the
world in front of a panel of twenty industry expert judges, Donisi took home
First Place honors and a $200,000 award for their innovative solution to enable
in-home monitoring for key health bio-markers for patients with Congestive
Heart Failure (CHF) and other chronic diseases.
Donisi has the only clinically validated, contact-free technology that can
detect signs of pulmonary congestion remotely, supporting the continuum of care
for remote patient monitoring and hospital-at-home services. Based upon
FDA-cleared technology and backed by 11 granted patents, Donisi’s AI-based
system detects and analyzes multiple health bio-indicators simultaneously -
without the need to remove clothing or connect the patient to wires or patches
- delivering clinically meaningful insights and notifications of changes in key
health indicators.
“We are honored to be recognized by this prestigious institution, and are
grateful to the ICI team for highlighting our breakthrough technology’s
potential to meaningfully improve cardiovascular health,” said Donisi’s CEO
Yair Brosh. “We are focused on developing solutions for chronic patients at
home, with a goal to reduce readmission rates for CHF patients..”
In the United States, CHF is the #1 cause of readmission among Medicare (65+)
patients, with at least 20% of patients readmitted within 30 days and 50%
within 6 months. With an average cost of readmissions in the tens of thousands
of dollars per patient, direct medical costs for CHF in the US total over $21.7
billion annually.
”This doesn’t need to be the case,” said Donisi’s new Chief Medical Officer,
Dr. Shaddy Hassan. “It is known that when heart failure exacerbations are
detected early, and healthcare teams intervene while patients are still at home
before their condition worsens, many of these costly readmissions can be
avoided, resulting in significant cost reduction and improved quality of life.”
This award marks the latest in a highly successful year for the HealthTech
Startup beginning with a $1M BIRD grant [
awarded in partnership with Dell Technologies in January, scientific article
publication [
https://www.tandfonline.com/doi/abs/10.1080/03091902.2021.1905896?journalCode=ijmt20],
a de novo FDA clearance and First Place at MEDinISRAEL
[https://vimeo.com/535866905] in April, and Future Unicorn award by E&T
Magazine [
https://finance.yahoo.com/news/donisi-health-named-2021s-future-105300198.html?.tsrc=fin-srch],
among others.
For more information please contact:
Hannah Carimi
Donisi Health, Israel
hannah.carimi@donisihealth.com
Michael Seggev
Donisi Health, US
michael.seggev@donisihealth.com
Photo - https://mma.prnewswire.com/media/1705485/Donisi_Health_Wins_ICI.jpg
Source: ContinUse Biometrics, dba Donisi Health, Donis
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。